Is cetirizine and topical betamethasone (0.05%) cream safe to use during pregnancy?

Cetirizine and Topical Betamethasone 0.05% Cream in Pregnancy

Both cetirizine and topical betamethasone 0.05% cream can be used during pregnancy, but betamethasone should be limited to the smallest effective area and shortest duration necessary, particularly avoiding very large surface areas or prolonged continuous use.

Cetirizine Safety Profile

Cetirizine is relatively safe for use throughout pregnancy based on substantial evidence:

• Large-scale safety data from over 1.2 million pregnancies show no statistically significant associations with major congenital malformations, spontaneous abortions, or preterm births 1
• Multiple cohort studies totaling over 186,000 exposures in Scandinavian registries confirm a favorable safety profile 1
• Specific observational data from 228 pregnancies with cetirizine exposure showed 83.7% resulted in live births, with only 2 congenital malformations reported (within background rates) 2
• Meta-analyses confirm cetirizine is not associated with clinically important increases in adverse fetal outcomes 3

However, the FDA label recommends consulting a health professional before use during pregnancy 4, reflecting regulatory caution despite reassuring research data.

Topical Betamethasone 0.05% Safety Considerations

Betamethasone 0.05% is a high-potency topical corticosteroid that requires more careful consideration:

Key Safety Points:

• FDA Pregnancy Category C: Animal studies show teratogenic effects, but adequate human studies are lacking 5
• Use only if potential benefit justifies potential risk to the fetus 5
• Should not be used extensively, in large amounts, or for prolonged periods during pregnancy 5

Evidence-Based Risks:

The most comprehensive evidence comes from a Cochrane review of 1,601,515 subjects 6:

• No increased risk for: major congenital abnormalities (RR 0.82,95% CI 0.34-1.96), preterm delivery (RR 0.93,95% CI 0.81-1.08), or low Apgar scores
• Potential concern for low birth weight: Potent to very potent corticosteroids showed a trend toward increased risk (RR 1.58,95% CI 0.96-2.58), particularly with very large cumulative doses 6
• A large UK cohort study (84,133 pregnancies) found significant association between potent/very potent topical corticosteroids and fetal growth restriction 7

Clinical Guideline Recommendations:

The European Dermatology Forum S3 guideline states that mild/moderate topical corticosteroids are preferred over potent/very potent ones in pregnancy due to the associated risk of fetal growth restriction 7.

Practical Management Algorithm

For pregnant patients needing both medications:

1. Cetirizine: Can be used throughout pregnancy with reasonable confidence

   • Standard adult dose: 10 mg once daily
   • Extensive safety data supports use in all trimesters
   • Particularly safe based on >186,000 documented exposures

2. Betamethasone 0.05% cream: Use with specific precautions

   • Limit to smallest effective area (avoid large surface areas)
   • Use shortest duration possible to control symptoms
   • Avoid occlusive dressings which increase systemic absorption 5
   • Monitor for HPA axis suppression if using on large areas 5
   • Consider switching to lower potency alternatives (mild-moderate strength) if prolonged use is anticipated

3. For atopic dermatitis specifically: Guidelines support intermittent use (2x weekly maintenance) of medium-potency steroids to prevent flares 8, but this evidence is not pregnancy-specific

Critical Caveats

• Systemic absorption risk: Betamethasone can cause HPA axis suppression, especially with large surface area application, prolonged use, or occlusive dressings 5
• Periocular use: Minimize betamethasone use near eyes due to unclear association with cataracts/glaucoma 8
• Breastfeeding: Cetirizine is not recommended during breastfeeding per FDA label 4; systemically absorbed corticosteroids are secreted in breast milk, so caution is advised 5
• First trimester exposure: While no clear teratogenic signal exists for either medication, the organogenesis period warrants particular attention to minimizing unnecessary exposures

The combination is acceptable when clinically indicated, but betamethasone should be used judiciously with attention to potency, surface area, and duration.